BioSpace News Archive

RaySearch Laboratories AB announces that the Mass General Cancer Center plans to expand its use of RayStation®* to proton treatment planning.

Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA.

Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay will conduct a series of meetings at the BIO Investor Forum, San Francisco on October 17-18, 2023.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced topline results from the INTUNE study in patients with idiopathic hypersomnia.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, is proud to announce the first U.S. installation of a Trinias SCORE Opera C12 (ceiling-mounted cutting edge angiography system) at Beaufort Memorial Hospital (Beaufort, SC).

VolitionRx Limited, a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader roundtable on sepsis management.

Boundless Bio today will present preclinical data on its second ecDNA-directed therapy (ecDTx), BBI-825, as well as present additional research on the intrinsic genomic plasticity of cancer cells enabled by ecDNA at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will discontinue the currently ongoing clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab.

Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.

FOXO Technologies Inc. announced that the United States Patent & Trademark Office has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers.